Dovepress

# ORIGINAL RESEARCH Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety

Samy Suissa<sup>1,2</sup>, Sophie Dell'Aniello<sup>1</sup>, Pierre Ernst

<sup>1</sup>Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada; <sup>2</sup>Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada

Correspondence: Samy Suissa, Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, 3755 Cote Ste-Catherine, H-461, Montreal, Québec, H3T IE2, Canada, Tel +1 514-340-7593, Fax +1 514-340-7564, Email samy.suissa@mcgill.ca

Purpose: Randomized trials report that single-inhaler triple therapy is more effective than dual bronchodilators at reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). However, this effect may have been influenced by the forced withdrawal of inhaled corticosteroids (ICS) at randomization. We used an adaptive selection new-user design to compare single-inhaler triple therapy with dual bronchodilators in real-world clinical practice.

Patients and Methods: We identified a cohort of COPD patients, 40 years or older, treated during 2017–2020, from the United Kingdom's Clinical Practice Research Datalink, a real-world practice setting. ICS-naïve patients initiating single-inhaler triple therapy or dual bronchodilators were compared on the incidence of COPD exacerbation and pneumonia over one year, after adjustment by propensity score weighting.

Results: The cohort included 4106 new users of single-inhaler triple therapy and 29,702 of dual bronchodilators. Single-inhaler triple therapy was the first maintenance treatment in 44% of the users and 43% had no COPD exacerbations in the prior year. The adjusted hazard ratio (HR) of a first moderate or severe exacerbation with triple therapy relative to dual bronchodilators was 1.08 (95% confidence interval (CI): 1.00-1.16). Among patients with two or more prior exacerbations the HR was 0.83 (95% CI: 0.74-0.92), while for those with prior asthma diagnosis it was 0.86 (95% CI: 0.70-1.06) and with blood eosinophil count >300 cells/µL it was 0.89 (95% CI: 0.76–1.05). The incidence of severe pneumonia was increased with triple therapy (HR 1.50; 95% CI: 1.29–1.75).

Conclusion: In a real-world setting of COPD treatment among ICS-naïve patients, thus unaffected by ICS withdrawal, single-inhaler triple therapy was not more effective than dual bronchodilators at reducing the incidence of exacerbation, except among patients with multiple exacerbations. Single-inhaler triple therapy should be initiated mainly in patients with multiple exacerbations while, for most others, dual bronchodilators are just as effective whilst avoiding the excess risk of severe pneumonias.

Keywords: cohort studies, COPD exacerbation, pneumonia, propensity scores, real-world evidence

#### Introduction

The recommended pharmacological treatment of chronic obstructive pulmonary disease (COPD) includes first longacting bronchodilators, namely long-acting muscarinic antagonists (LAMAs) and long-acting beta2-agonists (LABAs), or their combination.<sup>1</sup> Inhaled corticosteroids (ICS) are generally added with increasing disease severity or for specific patient profiles such as high eosinophil counts or frequent exacerbations. Currently, several combinations of these three treatment classes are available, including single-inhaler triple therapy.

Two large trials compared the effectiveness and safety of single-inhaler triple therapy with single-inhaler dual bronchodilator (combining LAMA and LABA) on major outcomes in patients with COPD.<sup>2,3</sup> The Informing the Pathway of COPD Treatment (IMPACT) and the Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) trials reported a significant reduction in the rate of COPD exacerbation and mortality with the triple inhaler compared with the dual bronchodilator.<sup>4,5</sup> However, these beneficial effects of triple therapy on reducing exacerbations

and mortality were limited to the early period after randomization, with no benefit observed during the subsequent follow-up.<sup>6,7</sup> Such an early benefit is compatible with an effect of abrupt ICS withdrawal at randomization among those allocated to LAMA-LABA.<sup>6–9</sup> Indeed, the reductions in exacerbations and mortality in the IMPACT trial were observed mainly among patients previously on ICS.<sup>4,10</sup> Adaptive selection trial designs for COPD treatments that tailor the randomisation scheme to the treatment already used by each subject at the time of trial enrolment have been proposed specifically to circumvent such effects of confounding by ICS discontinuation at randomization.<sup>11</sup>

In this paper, we report on an observational study that uses an adaptive selection design to compare the new singleinhaler triple with single-inhaler dual bronchodilator therapies in a real-world clinical practice setting.

# Methods

## Data Source

The study cohort was identified from the Clinical Practice Research Datalink (CPRD), a primary care database from the United Kingdom (UK) that contains primary care medical records for over 50 million people enrolled in more than 1800 general practices. Participating general practitioners in the CPRD-GOLD and Aurum networks record medical information as part of the routine care of patients, including demographic data, lifestyle factors, medical diagnoses recorded using Read and SNOMED codes, and prescriptions. Over 85% of the CPRD practices can be linked to the Hospital Episodes Statistics (HES) database. The CPRD population is representative of the overall population and these data sources have been validated.<sup>12–14</sup> The information on medications and diagnoses has been validated and shown to be of high quality, particularly for studies of COPD.<sup>13–17</sup>

# Study Design

The study cohort included all patients with a physician diagnosis of COPD who received a single-inhaler triple or a single-inhaler dual bronchodilator after 15 September 2017, the date the triple inhaler became available in the UK. All subjects had to be at least 40 years of age on the date of their first COPD diagnosis. The study was restricted to the larger Aurum database, as few eligible patients were available in the GOLD database, and to patients linkable to the Hospital Episodes Statistics (HES) database.

Cohort entry was taken as the date of the first prescription for a triple (LAMA-LABA-ICS) or a dual bronchodilator (LAMA-LABA) single-inhaler. The study cohort included all subjects with at least one year of medical history prior to cohort entry to allow a baseline period to measure the covariates and to identify new use of these study combinations. To apply the adaptive selection design, we only included patients who did not receive ICS during the baseline year or at cohort entry.<sup>11</sup>

We used an incident new-user cohort design to compare the initiators of triple therapy with the initiators of dual bronchodilators.<sup>18,19</sup> The subjects were stratified by their prior use of a LABA or LAMA (none, one, both) in the baseline year before initiating the study inhalers, to fit the adaptive selection trial design concept.<sup>11</sup> The propensity score of treatment initiation with triple therapy was thus estimated by logistic regression using all covariates, separately for the three prior LABA or LAMA treatment strata. Subjects in the study cohort were followed for up to one year from cohort entry, with follow-up ending at death, 31 March 2021, or the end of the patient's registration in the practice, whichever occurred first.

# **Outcome Events**

The main outcome was the occurrence of a moderate or severe exacerbation of COPD, while severe exacerbation of COPD, severe pneumonia and all-cause mortality were also identified, all during the one-year follow-up. A moderate exacerbation was defined by a new prescription for prednisolone, while a severe exacerbation was defined as a hospitalization for COPD (ICD-10: J41, J42, J43, J44). Severe pneumonia was defined as a hospitalization for community-acquired pneumonia (ICD10: J10.0; J11.0; J12-J18; J22; J69; J85.0; J85.1; J86). These diagnostic codes have been shown to have good accuracy and were used in several studies of COPD using the CPRD.<sup>16,17,20-22</sup>

# Covariates

The covariates used to compute the propensity score of treatment initiation included several factors identified using lifestyle, clinical diagnoses, and prescriptions from CPRD and HES data. Age, sex, body mass index (BMI), smoking status and alcohol abuse were measured at or prior to cohort entry. The severity of COPD at treatment initiation was assessed by the number of prior moderate and severe COPD exacerbations, and the use of other respiratory drugs, during the baseline period, as well as by the percent predicted FEV<sub>1</sub>. A moderate exacerbation in the baseline year was defined by a new prescription for prednisolone. Other respiratory drugs included the number of prescriptions for short-acting inhaled beta-agonists and anticholinergics, methylxanthines, and antibiotics used for respiratory conditions. Prior use of a LABA or LAMA, alone or together, was matched on to satisfy the adaptive selection design. The most recent measures of dyspnea, FEV<sub>1</sub> and blood eosinophil count prior to cohort entry, were identified. Dyspnea was measured by mMRC, CAT score or the presence of dyspnea symptoms.<sup>23</sup> The percent predicted FEV<sub>1</sub> measurement, generally post-bronchodilator,<sup>24</sup> was calculated from the absolute FEV<sub>1</sub> value using age, sex and height, with race imputed as "Caucasian" for all.<sup>25</sup> Baseline co-morbidity in the year prior to cohort entry was measured using clinical diagnoses, hospitalizations and prescriptions (Table 1).

# Data Analysis

The propensity score of treatment initiation was estimated by logistic regression using all covariates, separately for the prior LAMA or LABA treatment strata. Fine stratification weights were computed using 100 strata defined by the

Table I Baseline Characteristics of the Study Cohort of 29,702 Initiators of Single-Inhaler Dual Bronchodilator Therapy and 4106Initiators of Single-Inhaler Triple Therapy, After Fine Stratification Weighting from Probability of Treatment Propensity Scores, withCorresponding Standardized Mean Differences

	Single-Inhaler Dual Bronchodilator	Single-Inhaler Triple Therapy	Standardized Mean Difference
Number of patients	29,702	4106	
Age at cohort entry, mean (sd)	70.1 (10.6)	70.2 (10.9)	0.0049
Female sex, n (%)	13,399 (45.1)	1808 (44.0)	-0.0218
Current smoker, n (%)	16,189 (54.5)	2226 (54.2)	-0.0057
Obesity Status, n (%)			
Obese	8500 (28.6)	1171 (28.5)	-0.002 I
Non-Obese	19,396 (65.3)	2674 (65.1)	-0.0039
Missing data	1806 (6.1)	261 (6.4)	0.0118
Alcohol Abuse, n (%)	830 (2.8)	125 (3.0)	0.015
Blood eosinophils cells/µL*, mean (sd)	227.7 (179.1)	233.0 (183.5)	0.029
Blood eosinophil count %*, mean (sd)	3.0 (2.1)	3.1 (2.3)	0.0469
FEV <sub>1</sub> (% predicted)**, mean (sd)	60.0 (17.9)	59.8 (18.6)	-0.0101
FEV <sub>1</sub> /FVC <sup>†</sup> , mean (sd)	60.6 (13.5)	61.4 (14.2)	0.0579
Severity of dyspnea			
None-Mild	10,501 (35.4)	1470 (35.8)	0.0094
Moderate-Severe	14,377 (48.4)	1967 (47.9)	-0.0100
Missing	4824 (16.2)	669 (16.3)	0.0013
Respiratory events and medications in year prior to			
cohort entry, n (%)			
Hospitalization for COPD	2350 (7.9)	340 (8.3)	0.0131
Moderate/severe COPD exacerbation			
None	18,001 (60.6)	2480 (60.4)	-0.004
One	6993 (23.5)	979 (23.9)	0.0073
Тwo	2541 (8.6)	351 (8.6)	0.0001
Three or more	2167 (7.3)	295 (7.2)	-0.0044
Asthma diagnosis	2306 (7.8)	343 (8.3)	0.0215
Pneumonia hospitalization	2083 (7.0)	314 (7.6)	0.0241

(Continued)

#### Table I (Continued).

	Single-Inhaler Dual Bronchodilator	Single-Inhaler Triple Therapy	Standardized Mean Difference	
LAMA or LABA (no ICS)‡				
None	12,340 (41.5)	1799 (43.8)		
Any or both	17,362 (58.5)	2307 (56.2)		
Short-acting beta-agonists	23,996 (80.8)	3312 (80.7)	-0.0034	
Short-acting anti muscarinic	665 (2.2)	94 (2.3)	0.0026	
Prednisolone	10,490 (35.3)	1447 (35.2)	-0.0015	
Methylxanthines	102 (0.3)	16 (0.4)	0.0061	
Respiratory antibiotics	17,883 (60.2)	2483 (60.5)	0.0057	
Comorbidity in year prior to cohort entry, n (%)				
Cancer	2211 (7.4)	306 (7.5)	0.0007	
Heart failure	3161 (10.6)	456 (11.1)	0.0146	
Myocardial infarction (hospitalized)	296 (1.0)	42 (1.0)	0.0016	
Stroke (hospitalized)	738 (2.5)	112 (2.7)	0.0155	
Renal disease	2215 (7.5)	302 (7.4)	-0.0040	
Diabetes	7602 (25.6)	1044 (25.4)	-0.004 I	
Other medication use in year prior to cohort entry,				
n (%)				
ACE-inhibitors	7865 (26.5)	1127 (27.4)	0.0218	
ARBs	3292 (11.1)	468 (11.4)	0.0102	
Beta-blockers	7865 (26.5)	1097 (26.7)	0.0055	
Calcium-channel blockers	8151 (27.4)	1121 (27.3)	-0.0029	
Thiazide diuretics	2737 (9.2)	385 (9.4)	0.0058	
Antiarrhythmics	562 (1.9)	82 (2.0)	0.0075	
Aspirin	6213 (20.9)	867 (21.1)	0.0048	
Oral anticoagulant	3927 (13.2)	581 (14.1)	0.0268	
Statins	14,924 (50.2)	2098 (51.1)	0.0172	
PPIs	14,024 (47.2)	1914 (46.6)	-0.0121	
NSAIDs	3132 (10.5)	422 (10.3)	-0.0085	
Opioids	11,088 (37.3)	1523 (37.1)	-0.005 I	

Notes: \*Based on available data from 86% for EOS count (cells/uL) and 86% for EOS count (%). \*\* Based on available data from 63% of subjects. † Based on available data from 45% of subjects. ‡ Stratification factor, not weighted. Propensity scores computed separately for each stratum.

propensity score to create comparable treatment arms with the same covariate distribution as the study cohort, within each prior treatment stratum.<sup>26</sup> Standardized mean differences of covariates were computed to assess the comparability of the two treatment groups. Rates of outcomes were computed crudely and weighted, after stratification by prior treatment. A weighted Cox proportional hazard regression with a robust variance estimator, with stratification by prior treatment strata, was used in an as-treated analysis to compare triple with dual therapy on the risks of COPD exacerbation, death, and severe pneumonia during the first year after treatment initiation. Continuing exposure was measured by successive prescriptions of the initial single-inhaler treatment with a maximal 60-day gap between the prescription dates, with current use exposure ending 60 days after the last such prescription date. The comparative analysis was stratified by the number of exacerbations during the baseline year, by prior asthma diagnosis, and by baseline blood eosinophil counts as <150, 150–300, and >300 cells/ $\mu$ L, using the weighted regression model with an interaction term between these factors and the treatment.

Sensitivity analyses included an intention-to-treat analysis over the one-year follow-up. The definition of continuous use for the as-treated analyses was evaluated by varying the prescription gap to 30 and 90 days. The analysis was stratified by the presence of prior LAMA or LABA treatment. The analysis was also restricted to the subgroup of users of the single-inhaler combinations used in the IMPACT trial (fluticasone furoate-vilanterol-umeclidinium versus dual

vilanterol-umeclidinium) and in the TRIBUTE trial (beclomethasone-formoterol-glycopyrronium versus indacaterolglycopyrronium).<sup>27</sup> Finally, we used an alternative definition for a moderate or severe exacerbation that has been validated in the CPRD.<sup>28</sup> It is defined by an outpatient or inpatient diagnosis of lower respiratory tract infection (LRTI) or acute exacerbation of COPD (AECOPD), or a prescription of COPD-specific antibiotics combined with an oral corticosteroid, or a record of two or more respiratory symptoms of acute exacerbation of COPD along with a prescription of COPD-specific antibiotics and/or an oral corticosteroid on the same day. All analyses were conducted using SAS version 9.4. The study protocol was approved by the Independent Scientific Advisory Committee of the CPRD (Protocol 21\_000491) and the Ethics Committee of the Jewish General Hospital (JGH Protocol #17-137), Montreal, Quebec, Canada.

### Results

The study cohort included 4122 new users of triple therapy and 29,779 new users of dual bronchodilators, after excluding patients with no COPD diagnosis, users of ICS prior to treatment initiation, and the few patients (1259) contributed by the GOLD database (Figure 1). As there were only 245 new users of triple therapy that had used both a LABA and LAMA (in separate inhalers) in the baseline year, we regrouped the three baseline long-acting bronchodilator groups into two categories, any use or no use of LABA or LAMA. Thus, propensity scores were computed separately for these two strata only. The baseline characteristics, comparing initiators of single-inhaler triple therapy with initiators of dual bronchodilators after weighting by fine stratification of propensity scores and averaging over the two strata, show that the two groups are well-balanced (Table 1). The unweighted baseline characteristics of the two treatment groups are provided in <u>Table S1</u>. Of note, the unweighted data show that single-inhaler triple therapy users had no COPD exacerbation in the year prior to initiation (Table S1). The adjusted characteristics, after weighting by fine stratification of propensity users had no COPD exacerbation in the year prior to initiation (Table S1). The adjusted characteristics, after weighting by fine stratification of propensity users had no COPD exacerbation in the year prior to initiation (Table S1). The adjusted characteristics, after weighting by fine stratification of propensity scores, stratified by prior use of a LABA or LAMA, are provided in <u>Tables S2</u> and <u>S3</u>.




Figure I Flowchart of cohort selection.




Figure 2 Kaplan-Meier curves for the one-year cumulative incidence of the first moderate or severe COPD exacerbation comparing single-inhaler triple therapy with single-inhaler dual bronchodilators in patients with COPD in the first year after treatment initiation, from the as-treated analysis, after adjustment by inverse probability of treatment weights.

The single-inhaler triple therapy group included beclomethasone dipropionate-formoterol-glycopyrronium (57%) and fluticasone furoate-vilanterol-umeclidinium (43%), while the single-inhaler dual bronchodilators included vilanterol-umeclidinium (51%), olodaterol-tiotropium (19%), indacaterol-glycopyrronium (17%) and formoterol-aclidinium (13%). The mean duration of continuous treatment was 6 months in each of the two arms, with 4.8% of the dual bronchodilator patients switching to a triple inhaler during the one-year follow-up and 1.8% doing the reverse.

The cumulative incidence of a first moderate or severe exacerbation over 1 year was approximately 40% for the two treatment groups (Figure 2). The corresponding adjusted hazard ratio (HR) of a first moderate or severe exacerbation associated with triple therapy relative to dual bronchodilators was 1.08 (95% confidence interval (CI): 1.00–1.16)

	Number of Patients	Number with Events	Person- Years	Rate* Per 100 Per Year	Rate† Per 100 Per Year	Adjusted† HR (95% CI)
Moderate or severe						
exacerbation						
Triple therapy	4106	1304	1494	86.6	64.8	1.08 (1.00–1.16)
Dual bronchodilator	29,702	7030	12,344	56.1	59.1	1.00 (Reference)
Severe exacerbation						
Triple therapy	4106	283	1961	14.4	10.1	1.32 (1.13–1.55)
Dual bronchodilator	29,702	1029	14,739	7.0	7.6	I.00 (Reference)
All-cause mortality						
Triple therapy	4106	275	2034	13.3	9.6	1.53 (1.30–1.79)
Dual bronchodilator	29,702	900	14,970	6.0	6.3	I.00 (Reference)
Severe pneumonia						
Triple therapy	4106	317	1966	15.9	11.7	1.50 (1.29–1.75)
Dual bronchodilator	29,702	1079	14,740	7.3	7.8	I.00 (Reference)

**Table 2** Adjusted Hazard Ratios of COPD Exacerbation, Mortality and Severe Pneumonia Comparing Single-Inhaler Triple Therapywith Single-Inhaler Dual Bronchodilator Therapy in Patients with COPD in the First Year After Treatment Initiation, from the as-Treated Analysis

Notes: \*Crude, computed before weighing by fine stratification of propensity scores. † After weighting by fine stratification weights from the probability of treatment propensity scores, stratified by prior use of LAMA or LABA.

(Table 2). The HR of a severe exacerbation with triple therapy was 1.32 (95% CI: 1.13–1.55), while for all-cause mortality it was 1.53 (95% CI: 1.30–1.79) and for severe pneumonia 1.50 (95% CI: 1.29–1.75), relative to dual bronchodilators (Table 2).

Stratification by patient phenotypes shows that single-inhaler triple therapy is associated with a 17% lower incidence of moderate or severe exacerbation among patients with two or more exacerbations in the year prior to cohort entry (HR 0.83; 95% CI: 0.74–0.92), but a higher incidence among patients with one or no prior exacerbations (Table 3). A similar trend is observed for patients with a prior diagnosis of asthma (HR 0.86; 95% CI: 0.70–1.06) and those with a blood eosinophil count >300 cells/ $\mu$ L (HR 0.89; 95% CI: 0.76–1.05), albeit not reaching statistical significance. In contrast, the incidence is elevated with triple therapy in patients with no prior asthma diagnosis or those with blood eosinophil count <=300 cells/ $\mu$ L (Table 3).

**Table 3** Adjusted Hazard Ratios of a Moderate or Severe COPD Exacerbation Comparing Single-Inhaler Triple Therapy with Single-Inhaler Dual Bronchodilator Therapy in Patients with COPD in the First Year After Treatment Initiation, from the as-Treated Analyses Over One-Year Follow-Up, Stratified by Number of Exacerbations in the Prior Year, Prior Asthma, and Baseline Peripheral Blood Eosinophil Count

	Number of Patients	Number with Events	Person- Years	Rate* Per 100 Per Year	Rate† Per 100 Per Year	Adjusted† HR (95% CI)
Overall						(10/1-04)
Triple therapy	4106	1304	1494	86.6	64.8	1.08 (1.00-1.16)
Dual bronchodilator	29,702	7030	12,344	56.1	59.1	1.00 (Reference)
COPD exacerbations in	29,702	7030	12,344	50.1	57.1	1.00 (Reference)
prior year None						
	1754	271	72.1	27.2	24.0	
Triple therapy	1754	271	731	37.2	34.8	1.19 (1.02–1.39)
Dual bronchodilator	18,738	2435	8551	28.5	28.7	1.00 (Reference)
One						
Triple therapy	1222	430	434	98.7	98.4	1.17 (1.04–1.32)
Dual bronchodilator	6731	2174	2620	82.1	82.4	I.00 (Reference)
Two or more						
Triple therapy	1130	603	330	182.9	169.1	0.83 (0.74-0.92)
Dual bronchodilator	4233	2421	1174	206.2	209.4	I.00 (Reference)
Prior asthma diagnosis						
None						
Triple therapy	3553	1129	1296	86.4	65.2	1.10 (1.01–1.19)
Dual bronchodilator	27,630	6493	11,534	55.5	58.1	I.00 (Reference)
Yes						
Triple therapy	553	175	198	88.1	62.3	0.86 (0.70-1.06)
Dual bronchodilator	2072	537	810	66.1	72.9	I.00 (Reference)
Baseline blood eosinophil						
count (cells/µL)						
< 150						
Triple therapy	1191	382	412	92.2	67.6	1.12 (0.98-1.29)
Dual bronchodilator	9445	2201	3921	55.6	58.6	1.00 (Reference)
150-300	7115	2201	5721	55.0	50.0	
Triple therapy	1501	472	539	86.6	67.2	1.13 (0.99–1.28)
Dual bronchodilator	11,285	2644	4722	54.9	57.5	1.13 (0.99–1.28) 1.00 (Reference)
>300	11,205	2044	4/22	54.7	57.5	1.00 (Reference)
	700	274	205	00.4	(2.5	0.00 (0.74 + 0.5)
Triple therapy	799	274	305	88.4	62.5	0.89 (0.76–1.05)
Dual bronchodilator	4764	1314	1900	68.1	71.9	1.00 (Reference)

Notes: \*Crude, computed before weighing by fine stratification of propensity scores. †After weighting by fine stratification weights from the probability of treatment propensity scores, stratified by prior use of LAMA or LABA.

Table 4 Adjusted Hazard Ratios of a Moderate or Severe COPD Exacerbation Comparing Single-Inhaler Triple Therapy with Single-
Inhaler Dual Bronchodilator Therapy in Patients with COPD in the First Year After Treatment Initiation, from the as-Treated
Sensitivity Analyses

	Number of Patients	Number with Events	Person- Years	Rate* Per 100 Per Year	Rate† Per 100 per Year	Adjusted† HR (95% CI)
Primary as-treated analysis						
Triple therapy	4106	1304	1494	86.6	64.8	1.08 (1.00–1.16)
Dual broncho	29,702	7030	12,344	56.1	59.1	1.00 (Reference)
Intent-to-treat analysis (one year)						
Triple therapy	4106	1684	2279	73.8	53.6	1.05 (0.98-1.12)
Dual bronchodilator	29,702	9566	19,577	48.4	50.8	1.00 (Reference
Using validated definition of COPD						
exacerbation‡						
Triple therapy	4106	1339	1499	88.7	69.8	1.16 (1.07–1.25)
Dual bronchodilator	29,702	7110	12,356	56.9	59.5	1.00 (Reference
Continuous use defined by 30-day						-
gap						
Triple therapy	4106	727	607	9.	87.4	1.05 (0.95–1.16
Dual bronchodilator	29,702	3658	4633	78.1	83.0	I.00 (Reference
Continuous use defined by 90-day						·
gap						
Triple therapy	4106	1487	1832	80.7	59.1	1.06 (0.99–1.14
Dual bronchodilator	29,702	8116	15,333	52.3	55.0	I.00 (Reference
Initial treatment, no prior LABA						·
or LAMA						
Triple therapy	1799	478	635	75.2	58.0	1.12 (0.99–1.28)
Dual bronchodilator	12,340	2356	4921	47.8	50.3	I.00 (Reference
Treatment stepped up from LABA						·
or LAMA						
Triple therapy	2307	826	859	96.1	70.7	1.05 (0.96-1.15)
Dual bronchodilator	17,362	4674	7423	62.9	66.4	I.00 (Reference
Fluticasone furoate-vilanterol-						
umeclidinium versus vilanterol-						
umeclidinium						
Triple therapy	1757	525	690	74.8	59.5	1.08 (0.96-1.21)
Dual bronchodilator	15,224	3303	6408	51.7	54.5	I.00 (Reference
Beclomethasone-formoterol-						,
glycopyrronium versus indacaterol-						
glycopyrronium						
Triple therapy	2349	779	805	97.0	69.9	1.08 (0.97-1.21)
Dual bronchodilator	5059	1297	2130	58.9	62.4	I.00 (Reference

**Notes**: \*Crude, computed before weighing by fine stratification of propensity scores. †After weighting by fine stratification weights from the probability of treatment propensity scores, stratified by prior use of LAMA or LABA. ‡COPD exacerbation defined as an outpatient or inpatient diagnosis of LRTI or AECOPD, or a prescription of COPD-specific antibiotic combined with OCS, or a record of two or more respiratory symptoms of AECOPD along with a prescription of COPD-specific antibiotics and/or OCS on the same day, as per Rothnie et al.<sup>28</sup>

Sensitivity analyses mainly confirmed the robustness of the results (Table 4). As expected, the HR was slightly attenuated in the intention-to-treat analysis over the one-year follow-up (HR 1.05; 95% CI: 0.98–1.12). Using the alternative definition of exacerbation and varying the gap between prescriptions to define continuous treatment did not significantly alter the main result. The stratified analysis by whether the single inhalers were used de novo or stepped up from a LAMA or LABA did not affect the findings. Finally, the analysis restricted to the subgroup of users of the single-inhaler combinations used in the IMPACT trial (fluticasone furoate-vilanterol-umeclidinium versus vilanterol-umeclidinium) and in the TRIBUTE trial (beclomethasone-formoterol-glycopyrronium versus indacaterol-glycopyrronium) produced consistent findings.

## Discussion

This first real-world observational study of single-inhaler triple therapy in COPD suggests that patients prescribed triple therapy had a similar incidence of moderate or severe exacerbation over the first year of use as those treated with a single-inhaler dual bronchodilator. However, the incidence was significantly lower with triple therapy for the subgroup of patients with two or more exacerbations in the year prior to treatment initiation and numerically lower for patients with a prior diagnosis of asthma and those with an elevated blood eosinophil count (>300 cells/ $\mu$ L). On the other hand, the incidence of a COPD exacerbation was slightly higher with triple therapy for those patients who did not have these three phenotypes. The incidence of severe exacerbation and severe pneumonia requiring hospitalization, and all-cause mortality, was higher with the single-inhaler triple combination compared with a dual bronchodilator.

The findings of our observational study differ from those reported in the large IMPACT and ETHOS randomized trials that found significant reductions in the incidence of moderate or severe exacerbation with single-inhaler triple therapy compared with dual bronchodilators.<sup>2,3</sup> Besides the observational nature of our study, several reasons can explain these differences. First, the patients enrolled in these trials included 40% who were already treated with triple therapy and 70–80% whose treatment involved ICS. The abrupt withdrawal of prior ICS treatment at randomization imposed by the trials' design can bias the results.<sup>29</sup> Second, the trials included COPD patients with a history of asthma and with multiple COPD exacerbations, patients for whom ICS are indicated and should not be withdrawn. Together, these two issues will distort the results.<sup>6–8</sup> On the other hand, our real-world study population was restricted to patients not previously treated with an ICS, thus avoiding the confounding effects of abruptly withdrawing prior ICS use. Thus, while the effectiveness with triple therapy compared with dual bronchodilators reported in the trials can be in great part attributed to the effect of abrupt ICS withdrawal, our observational study avoids this issue by its use of an adaptive selection design.

While the IMPACT and ETHOS trials reported significant overall reductions in all-cause mortality comparing singleinhaler triple therapy with dual bronchodilators, with HRs of 0.72 (95% CI: 0.53–0.99) and 0.51 (95% CI: 0.33–0.80), respectively, this effect was observed exclusively in patients who had to discontinue ICS at randomization. Indeed, among non-users of ICS prior to randomization, the HRs of all-cause mortality comparing triple therapy with dual bronchodilators were 1.25 (95% CI: 0.60–2.59) in IMPACT and 1.49 (95% CI: 0.49–4.55) in ETHOS.<sup>4,5</sup> These estimates, unimpacted by the effect of abrupt ICS withdrawal at randomization, are more in line with the corresponding HR of all-cause mortality of 1.53 (95% CI: 1.30–1.79) found in our observational study that excluded patients already treated with ICS.

Our study identified several noteworthy and non-recommended patterns of triple therapy prescribing in this real-world clinical practice setting. First, single-inhaler triple therapy was the very first maintenance treatment in 44% of the patients who used this inhaler, with no LABA, LAMA or ICS in the year prior to initiation. This is rather discordant with the GOLD evidence-based recommendations for the initial treatment of COPD, which advocate mainly a LAMA, a LABA, their combination, or a LABA-ICS for patients with eosinophilia, but not triple therapy.<sup>1</sup> Second, 43% of triple therapy users had no COPD exacerbation in the year prior to initiation and would not have been eligible for the IMPACT and ETHOS trials. In addition, 31% had no or mild dyspnea, and 81% had a blood eosinophil count <300 cells/ $\mu$ L. While triple therapy is not generally recommended for these patient profiles, there are no randomized controlled data on the impact of this treatment in the many such patients prescribed triple therapy in our real-world clinical setting. Indeed, the trials of triple therapy included only patients with a history of exacerbations, with moderate or severe dyspnea, and with long-standing disease.

Our stratified analyses are quite revealing with respect to the treatment for these non-recommended patient profiles. Indeed, single-inhaler triple therapy was associated with a significantly lower incidence of moderate or severe exacerbation among patients with two or more exacerbations in the year prior to starting treatment, as per recommendations, but a higher incidence among patients with less than two prior exacerbations. Similarly, for patients with a prior diagnosis of asthma and those with a blood eosinophil count >300 cells/ $\mu$ L, the incidence of exacerbation was also lower with triple therapy, though not reaching statistical significance.

We found a 50% increased incidence of severe pneumonia requiring hospitalization with triple therapy compared with dual bronchodilators. This is consistent with the 65% and 78% increases in serious pneumonias with triple therapy reported in the IMPACT and ETHOS trials, respectively.<sup>2,3</sup>

Our study has several strengths and limitations. First, the new-user design identified study subjects at the time of initiation of the single-inhaler triple and dual bronchodilator therapies, thus emulating the randomized trial approach in an observational setting, albeit without randomization. Second, our adaptive selection study design excluded patients treated with ICS that made up 70-80% of the patients in the IMPACT and ETHOS trials, including 40% already using triple therapy. Consequently, our design avoided the confounding effect of prior ICS use that affected the two randomized trials. Third, the observational setting of general clinical practice provides real-world evidence on the effects of these treatments. Fourth, several of the outcome events used validated definitions, including hospitalization and death records, and thus less subject to misclassification errors.<sup>15,16</sup> The study has limitations. First, the treatment exposure measures are based on written prescriptions, not necessarily dispensed, which could introduce some misclassification, potentially compounded by the less-than-optimal inhaler technique in the real-world setting. Second, the continuous treatment duration was relatively short (mean 6 months), which reflects the real-world clinical situation, though the intent-to-treat analysis which used the entire one-year follow-up supported the findings of the as-treated analysis. Third, with the 40 years of age cut-off, the use of physician diagnoses to identify the cohort of patients with COPD may have misclassified some patients with asthma as COPD, which would anyhow tend to favor the triple inhaler. However, the physician diagnosis of COPD was validated and found to be accurate, with spirometry only marginally improving accuracy.<sup>15</sup> Fourth, while large, the study size is limited by the number of new users of single-inhaler triple therapy (4106) who did not use ICS previously, thus limiting the power of stratified analyses, particularly for the less common outcomes of severe exacerbation and all-cause mortality. Fifth, the study involved two different triple inhalers and four dual bronchodilators, which could have different effects on the outcome. However, the analysis restricted to the singleinhaler combinations studied in the IMPACT and TRIBUTE trials produced consistent findings. Finally, residual confounding cannot be ruled out in any observational study, despite the use of propensity score weighting which created groups highly comparable on all available measures of patient characteristics, including COPD severity.

# Conclusion

While randomized controlled trials provide evidence for the effectiveness of treatments for COPD, observational studies are now receiving special attention in providing complementary real-world evidence (RWE) for regulatory decision-making.<sup>30–32</sup> This observational study, conducted in a real-world clinical practice setting of COPD treatment among ICS-naïve patients, using an adaptive selection design, found that single-inhaler triple therapy was not more effective than dual bronchodilators at reducing the incidence of exacerbation, except among patients with multiple exacerbations. Thus, single-inhaler triple therapy should be mainly reserved for patients with multiple exacerbations and likely those with asthma and eosonophilia while, for most others, dual bronchodilators are just as effective whilst circumventing the excess risk of severe pneumonias with triple therapy. These latter patients, for whom the GOLD reports do not recommend triple therapy, made up a large proportion of the patients prescribed single-inhaler triple therapy in this real-world clinical practice setting.

# Abbreviation

AECOPD, acute exacerbation of COPD; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; ETHOS, Efficacy and Safety of Triple Therapy in Obstructive Lung Disease; HES, Hospital Episodes Statistics; HR, hazard ratio; ICS, inhaled corticosteroids; LAMA, long-acting muscarinic antagonists; LABA, long-acting beta<sub>2</sub>-agonists; LRTI, lower respiratory tract infection; IMPACT, Informing the Pathway of COPD Treatment; UK, United Kingdom; sd, standard deviation.

# **Data Sharing Statement**

This study is based in part on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the UK National Health Service as part of their care and support. The interpretation and conclusions contained in this study are those of the author/s alone. Because electronic health records are classified as "sensitive data" by the UK Data Protection Act, information governance restrictions (to protect patient confidentiality) prevent data sharing via public deposition.

Data are available with approval through the individual constituent entities controlling access to the data. Specifically, the primary care data can be requested via application to the Clinical Practice Research Datalink (https://www.cprd.com).

# **Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

# Funding

This study is not funded. Pr. Suissa is the recipient of the Distinguished James McGill Professorship award.

# Disclosure

SS attended scientific advisory committee meetings or consulted for AstraZeneca, Atara, Bristol-Myers-Squibb, Merck, Novartis, Panalgo, Pfizer and Seqirus, and received speaking fees from AstraZeneca, Boehringer-Ingelheim and Novartis. Dr. Ernst and Ms Dell'Aniello have no conflicts of interest.

# References

- 1. Vogelmeier CF, Criner GJ, Martinez FJ., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD Executive Summary. *Eur Respir J.* 2017;49(3):548. doi:10.1183/13993003.00214-2017
- 2. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378 (18):1671–1680. doi:10.1056/NEJMoa1713901
- 3. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. *N Engl J Med.* 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
- 4. Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2020;201(12):1508–1516. doi:10.1164/rccm.201911-2207OC
- 5. Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ethos trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. a randomized, double-blind, multicenter, parallel-group study. *Am J Respir Crit Care Med.* 2021;203(5):553–564. doi:10.1164/rccm.202006-2618OC
- 6. Suissa S, Drazen JM. Making sense of triple inhaled therapy for COPD. N Engl J Med. 2018;378(18):1723–1724. doi:10.1056/NEJMe1716802
- 7. Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. *Eur Respir J.* 2018;52(6):1801848. doi:10.1183/13993003.01848-2018
- 8. Wedzicha JA, Banerji D, Kostikas K. Single-inhaler triple versus dual therapy in patients with COPD. N Eng J Med. 2018;379(6):590-593.
- Suissa S. Perplexing mortality data from triple therapy trials in COPD. *Lancet Respir Med.* 2021;9(7):684–685. doi:10.1016/S2213-2600(21)00238-1
  Han MK, Dransfield MT, Dransfield MT, et al. The effect of ICS withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. *Am J Respir Crit Care Med.* 2020;202(9):1237–1243. doi:10.1164/rccm.201912-24780C
- 11. Suissa S. Triple Therapy in COPD: time for adaptive selection trials. *COPD*. 2021;18(6):597–601. doi:10.1080/15412555.2021.1982886
- 12. Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48 (6):1740–1740g. doi:10.1093/ije/dyz034
- 13. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14. doi:10.1111/j.1365-2125.2009.03537.x
- 14. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44 (3):827–836. doi:10.1093/ije/dyv098
- Quint JK, Mullerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). *BMJ Open*. 2014;4(7):e005540. doi:10.1136/bmjopen-2014-005540
- Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. *Clin Epidemiol.* 2016;8:771–782. doi:10.2147/CLEP.S117867
- 17. Suissa S, Dell'Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. *Lancet Respir Med.* 2018;6(11):855–862. doi:10.1016/S2213-2600(18)30368-0
- 18. Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. *Pharmacoepidemiol Drug Saf.* 2013;22(1):1–6. doi:10.1002/pds.3334
- 19. Suissa S, Moodie EE, Dell'Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. *Pharmacoepidemiol Drug Saf.* 2017;26(4):459–468. doi:10.1002/pds.4107
- Meropol SB, Metlay JP. Accuracy of pneumonia hospital admissions in a primary care electronic medical record database. *Pharmacoepidemiol Drug Saf.* 2012;21(6):659–665. doi:10.1002/pds.3207
- Suissa S, Dell'Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in Real-world clinical practice. CHEST. 2019;155(6):1158–1165. doi:10.1016/j.chest.2019.03.005
- 22. Suissa S, Dell'Aniello S, Ernst P. Comparative effectiveness of initial LAMA versus LABA in COPD: real-world cohort study. J Chronic Obstructive Pulmonary Dis. 2021;18(1):1–8. doi:10.1080/15412555.2021.1877649

- 23. Rebordosa C, Plana E, Aguado J, et al. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). *Pharmacoepidemiol Drug Saf.* 2019;28(2):126–133. doi:10.1002/pds.4448
- 24. Whittaker HR, Pimenta JM, Jarvis D, Kiddle SJ, Quint JK. Characteristics associated with accelerated lung function decline in a primary care population with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2020;15:3079–3091. doi:10.2147/COPD.S278981
- 25. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J.* 2012;40(6):1324–1343. doi:10.1183/09031936.00080312
- 26. Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. *BMJ*. 2019;367:15657. doi:10.1136/bmj.15657
- 27. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet.* 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
- 28. Rothnie KJ, Müllerová H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. *PLoS One.* 2016;11(3):e0151357. doi:10.1371/journal.pone.0151357
- 29. Suissa S. Run-in bias in randomised trials: the case of COPD medications. Eur Respir J. 2017;49(6):1700361. doi:10.1183/13993003.00361-2017
- 30. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence what is it and what can it tell us? *N Engl J Med.* 2016;375(23):2293–2297. doi:10.1056/NEJMsb1609216
- Frieden TR, Drazen JM, Harrington DP, McMurray JJV, Ware JH, Woodcock J. Evidence for health decision making beyond randomized, controlled trials. N Engl J Med. 2017;377(5):465–475. doi:10.1056/NEJMra1614394
- 32. Eichler HG, Koenig F, Arlett P, et al. Are novel, nonrandomized analytic methods fit for decision making? The need for prospective, controlled, and transparent validation. *Clin Pharmacol Ther*. 2020;107(4):773–779. doi:10.1002/cpt.1638

International Journal of Chronic Obstructive Pulmonary Disease

#### **Dove**press

#### Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www. dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal